Politics

Marty Makary Resigns as FDA Commissioner Amid Policy Disputes

Illustration for: Marty Makary Resigns as FDA Commissioner Amid Policy Disputes
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

May 13, 2026

THE BARE STORY

Dr. Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday after serving for more than a year. The president announced the resignation on social media and appointed Kyle Diamantas, a deputy commissioner for food policy, to serve as acting commissioner. The president also publicly shared a text message from Makary highlighting his work on drug approval processes.

Makary’s departure followed reported disagreements between the commissioner and the administration. According to a senior administration official and sources familiar with the matter, tensions involved the slow implementation of policies, including the approval of flavored e-cigarettes. Furthermore, anti-abortion organizations had recently demanded Makary’s removal, accusing him of delaying a safety review of the abortion medication mifepristone that was requested by Health and Human Services Secretary Robert F. Kennedy Jr.

The resignation concludes a tenure marked by internal agency challenges. Senior FDA officials accused Makary of micromanagement, a lack of transparency, and mishandling a fast-track drug voucher program. The agency has recently experienced leadership turmoil, including the departure of several career scientists and reports of declining staff morale.

Makary, a surgeon who had previously criticized the government’s response to the COVID-19 pandemic, was confirmed to lead the FDA in March 2025. Following his departure, a scheduled Senate subcommittee hearing was postponed. As acting commissioner, Diamantas will inherit the ongoing mifepristone review and upcoming regulatory negotiations with the pharmaceutical industry.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Perspective by Grok

• Enforcing Executive Policy Mandates Valuing the rule of law and institutional hierarchy, this camp views administrative agencies as strictly subordinate to the elected executive branch. Makary’s failure to rapidly implement the administration’s core policies, including the delayed approval framework for e-cigarettes, represents unacceptable bureaucratic friction. His resignation is seen as a necessary enforcement of executive authority, ensuring that the FDA aligns with the authorized regulatory roadmap rather than operating as a rogue, slow-moving entity.

• Prioritizing Traditional Social Order Anchored in traditionalist values, this perspective views the stringent oversight of abortion medications as a fundamental moral and civic duty. The delay in completing the mifepristone safety review requested by HHS Secretary Kennedy is interpreted as an institutional failure to protect social order and uphold rigorous standards. By yielding to the demands of conservative advocacy groups, the administration successfully reaffirms its commitment to traditionalist principles and the strict scrutiny of morally contentious medical procedures.

• Restoring Institutional Management Discipline Prioritizing institutional continuity and operational stability, this side identifies Makary’s tenure as deeply disruptive to the FDA's core functioning. The allegations of micromanagement, lack of transparency, and the mishandling of fast-track voucher programs indicate a severe deficit in administrative competence. Appointing Kyle Diamantas as acting head is viewed as a pragmatic move to restore necessary operational discipline and steady leadership just as the agency enters critical negotiations with the pharmaceutical industry.

How it may affect me

As a U.S. reader:

• Short-term access to the abortion medication mifepristone may be affected as the new acting commissioner takes over an ongoing safety review prioritized by the administration.

• Consumers might soon see faster regulatory decisions or market availability for flavored e-cigarettes, as the agency aims to eliminate previous implementation delays.

• The speed and safety of new medications entering the market could change over the long term, depending on how new leadership manages the fast-track drug voucher program and upcoming negotiations with the pharmaceutical industry.

• The recent departure of career FDA scientists and internal morale issues could lead to long-term shifts in how rigorously the agency conducts independent safety reviews for food and drugs.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.